Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT ID: NCT07311850
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
3500 participants
INTERVENTIONAL
2025-12-29
2028-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MET097 Dose 1
Participants will receive MET097 administered subcutaneously
MET097
Once-weekly MET097 administered via subcutaneous injection
MET097 Dose 2
Participants will receive MET097 administered subcutaneously
MET097
Once-weekly MET097 administered via subcutaneous injection
MET097 Dose 3
Participants will receive MET097 administered subcutaneously
MET097
Once-weekly MET097 administered via subcutaneous injection
Placebo
Once-weekly placebo administered via subcutaneous injection
Placebo
Once-weekly placebo administered via subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MET097
Once-weekly MET097 administered via subcutaneous injection
Placebo
Once-weekly placebo administered via subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metsera
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site 97301-001007
Riverside, California, United States
Research Site 97301-001070
Torrance, California, United States
Research Site 97301-001077
Englewood, Colorado, United States
Research Site 97302-001001
Hollywood, Florida, United States
Research Site 97301-001309
Cary, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MET097-25-301
Identifier Type: -
Identifier Source: org_study_id